• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bausch Health Companies Inc. Common Stock (TSX:BHC)

    6.850 +0.030 (+0.44%)
    Streaming Delayed Price Updated: 2:01 PM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bausch Health Companies Inc. Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
    Via ACCESSWIRE
    News headline image
    Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
    Via ACCESSWIRE
    News headline image
    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces 2024 Annual Meeting of Shareholder Results
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces First Quarter 2024 Results
    Via ACCESSWIRE
    News headline image
    Salix Announces 2024 Gastrointestinal Health Scholars Program
    Via ACCESSWIRE
    News headline image
    CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
    Via ACCESSWIRE
    News headline image
    Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
    Via ACCESSWIRE
    News headline image
    Bausch Health to Announce First-Quarter 2024 Results on May 2
    Via ACCESSWIRE
    News headline image
    Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
    Via ACCESSWIRE
    News headline image
    Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
    Via ACCESSWIRE
    News headline image
    Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
    Via ACCESSWIRE
    News headline image
    Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
    Via ACCESSWIRE
    News headline image
    Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
    Via ACCESSWIRE
    News headline image
    Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
    Via ACCESSWIRE
    News headline image
    New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
    Via ACCESSWIRE
    News headline image
    Bausch Health Companies to Present at Cowen Annual Health Care Conference
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
    Via ACCESSWIRE
    News headline image
    Bausch Health Announces Board Refreshment
    Via ACCESSWIRE
    News headline image
    Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
    Via ACCESSWIRE
    News headline image
    CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
    Via ACCESSWIRE
    News headline image
    Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
    Via ACCESSWIRE
    News headline image
    DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
    Via ACCESSWIRE
    News headline image
    Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
    Via ACCESSWIRE
    News headline image
    The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
    Via ACCESSWIRE
    News headline image
    CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
    Via ACCESSWIRE
    News headline image
    As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.